Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

PURPOSE: Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the risk of developing MRONJ in patients who received ZA, denosumab, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikesue, Hiroaki, Doi, Kohei, Morimoto, Mayu, Hirabatake, Masaki, Muroi, Nobuyuki, Yamamoto, Shinsuke, Takenobu, Toshihiko, Hashida, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110486/
https://www.ncbi.nlm.nih.gov/pubmed/33791853
http://dx.doi.org/10.1007/s00280-021-04262-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110486/
https://www.ncbi.nlm.nih.gov/pubmed/33791853
http://dx.doi.org/10.1007/s00280-021-04262-w

Ejemplares similares